[go: up one dir, main page]

AU2001292019A1 - Protein prenyl transferase inhibitors in the treatment of neuroinflammatory disease - Google Patents

Protein prenyl transferase inhibitors in the treatment of neuroinflammatory disease

Info

Publication number
AU2001292019A1
AU2001292019A1 AU2001292019A AU9201901A AU2001292019A1 AU 2001292019 A1 AU2001292019 A1 AU 2001292019A1 AU 2001292019 A AU2001292019 A AU 2001292019A AU 9201901 A AU9201901 A AU 9201901A AU 2001292019 A1 AU2001292019 A1 AU 2001292019A1
Authority
AU
Australia
Prior art keywords
treatment
transferase inhibitors
prenyl transferase
neuroinflammatory disease
protein prenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001292019A
Inventor
Peter Adamson
John Greenwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Ophthalmology UCL
Original Assignee
Institute of Ophthalmology UCL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Ophthalmology UCL filed Critical Institute of Ophthalmology UCL
Publication of AU2001292019A1 publication Critical patent/AU2001292019A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001292019A 2000-09-29 2001-09-26 Protein prenyl transferase inhibitors in the treatment of neuroinflammatory disease Abandoned AU2001292019A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0023915.2 2000-09-29
GBGB0023915.2A GB0023915D0 (en) 2000-09-29 2000-09-29 Treatment of neuroinflammatory disease
PCT/GB2001/004291 WO2002040015A1 (en) 2000-09-29 2001-09-26 Protein prenyl transferase inhibitors in the treatment of neuroinflammatory disease

Publications (1)

Publication Number Publication Date
AU2001292019A1 true AU2001292019A1 (en) 2002-05-27

Family

ID=9900394

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001292019A Abandoned AU2001292019A1 (en) 2000-09-29 2001-09-26 Protein prenyl transferase inhibitors in the treatment of neuroinflammatory disease

Country Status (7)

Country Link
US (1) US20040019121A1 (en)
EP (1) EP1324757A1 (en)
JP (1) JP2004513922A (en)
AU (1) AU2001292019A1 (en)
CA (1) CA2460057A1 (en)
GB (1) GB0023915D0 (en)
WO (1) WO2002040015A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1558268A4 (en) * 2002-09-17 2008-09-17 Univ New York METHOD FOR TREATING AGE ASSOCIATED MEMORY DISORDERS (AAMI), EASY COGNITIVE IMPAIRMENT (MCI), AND CELL CYCLIC DISEASES
CA2513584A1 (en) * 2003-01-20 2004-08-05 Vib Vzw The use of yop proteins or rho gtpase inhibitors as caspase-1 inhibitors
JP2007529555A (en) * 2004-03-18 2007-10-25 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド How to treat synucleinopathy
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20060106060A1 (en) * 2004-03-18 2006-05-18 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
EP1744751A4 (en) * 2004-03-18 2010-03-10 Brigham & Womens Hospital TREATMENT OF SYNUCLEINOPATHIES
US8222293B2 (en) * 2004-05-24 2012-07-17 Regents of the University of Carolina Treating learning deficits with inhibitors of Hmg CoA reductase
WO2006052718A2 (en) 2004-11-05 2006-05-18 Janssen Pharmaceutica N.V. Farnesyltransferase inhibitors for treating sepsis
KR20080018874A (en) * 2005-04-27 2008-02-28 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. Materials and methods for promoting degradation of mutant proteins associated with human diseases
US20070032443A1 (en) * 2005-08-02 2007-02-08 Jaeseob Kim Therapy for Alzheimer's disease
WO2007015122A1 (en) * 2005-08-02 2007-02-08 Genexel, Inc. Therapy for alzheimer’s disease
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
WO2010057006A1 (en) * 2008-11-13 2010-05-20 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
WO2010063910A1 (en) * 2008-12-05 2010-06-10 Pharmaxon Use of geranyl-geranyl transferase in treating spinal cord lesions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2323783A (en) * 1997-04-02 1998-10-07 Ferring Bv Group Holdings Inhibitors of farnesyl protein transferase
TW527355B (en) * 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
US6428950B1 (en) * 1998-11-25 2002-08-06 Scios Inc. Assay to identify compounds that alter apolipoprotein E expression
US20020010128A1 (en) * 2000-04-13 2002-01-24 Parks Thomas P. Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism

Also Published As

Publication number Publication date
WO2002040015A8 (en) 2002-10-24
JP2004513922A (en) 2004-05-13
EP1324757A1 (en) 2003-07-09
GB0023915D0 (en) 2000-11-15
WO2002040015A1 (en) 2002-05-23
CA2460057A1 (en) 2002-05-23
US20040019121A1 (en) 2004-01-29

Similar Documents

Publication Publication Date Title
AU2001259758A1 (en) Interleukin-1 inhibitors in the treatment of diseases
AU2002310187A1 (en) Inhibitors of protein kinase for the treatment of disease
IL154016A0 (en) Pyrazole derivatives and their use as protein kinase inhibitors
AU2001270260A1 (en) 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
AU2002213485A1 (en) Inhibitors of protein kinases
PL375447A1 (en) Protein kinase inhibitors and uses thereof
IL151045A0 (en) 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
AU2001292019A1 (en) Protein prenyl transferase inhibitors in the treatment of neuroinflammatory disease
AU2002215261A1 (en) Method and arrangement for treatment of fluid
AU2002220266A1 (en) Methods for the identification and the treatment of cardiovascular disease
AU2576501A (en) Protein kinase inhibitors
AU2002220735A1 (en) Substituted derivatives of aminofuran-2-yl-acetic acid and aminothien-2-yl-acetic acid and the use thereof for treating migraines and pain
AU1189201A (en) Therapeutic compositions including protein kinase c inhibitors
AU2001255796A1 (en) (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
WO2002018574A3 (en) Human interleukin-four induced protein
SI1197485T1 (en) Cyclobuten-dione derivatives for use in the treatment of artherosclerosis
AU2001255730A1 (en) Methods and compositions for the treatment of cardiac indications
AU2002341828A1 (en) Enhanced proteins and methods for their use
AU2001263236A1 (en) Human myd88 adapter-like protein and functional fragments thereof
AU2001279090A1 (en) Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting protein kinases
AU2002342715A1 (en) Novel methods for the treatment and prevention of pain using stress-activated protein kinase inhibitors
AU2001263287A1 (en) Human protein kinase "13305" and uses therefor
AU2001285109A1 (en) Microtubule-associated proteins and tubulins
AU2001255168A1 (en) Compositions and methods for the treatment of immune related diseases
AU2001259564A1 (en) Pharmaceutical compositions and methods for use